{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:48:47Z","timestamp":1789145327703,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"publisher","award":["2017SGR1355"],"award-info":[{"award-number":["2017SGR1355"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"AGAUR","doi-asserted-by":"publisher","award":["2017SGR1562"],"award-info":[{"award-number":["2017SGR1562"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/01005"],"award-info":[{"award-number":["PI18\/01005"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/00552"],"award-info":[{"award-number":["PI21\/00552"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.biopha.2022.114079","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T23:44:59Z","timestamp":1670975099000},"page":"114079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Early treatment with JNJ-46356479, a mGluR2 modulator, improves behavioral and neuropathological deficits in a postnatal ketamine mouse model of schizophrenia"],"prefix":"10.1016","volume":"158","author":[{"given":"A.","family":"Mart\u00ednez-Pinte\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Madero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Prohens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Garc\u00eda-Rizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Parellada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gass\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.114079_bib1","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.114079_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.114079_bib3","first-page":"175","article-title":"The pharmacologic treatment of Schizophrenia-2021","volume":"325","author":"Goff","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2022.114079_bib4","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.biopha.2022.114079_bib5","doi-asserted-by":"crossref","unstructured":"Nucifora F.C.Jr, Mihaljevic M., Lee B.J., Sawa A. Clozapine as a model for antipsychotic development neurotherapeutics. 2017; 14: 750\u2013761. doi: 10.1007\/s13311\u2013017-0552\u20139.","DOI":"10.1007\/s13311-017-0552-9"},{"key":"10.1016\/j.biopha.2022.114079_bib6","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/archneur.63.10.1372","article-title":"Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations","volume":"63","author":"Lewis","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.biopha.2022.114079_bib7","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/pcn.12823","article-title":"Glutamate hypothesis in schizophrenia","volume":"73","author":"Uno","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.biopha.2022.114079_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41398-021-01385-9","article-title":"Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia","volume":"11","author":"Parellada","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.biopha.2022.114079_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011374","article-title":"Behavioral consequences of NMDA antagonist-induced neuroapoptosis in the infant mouse brain","volume":"5","author":"Yuede","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.114079_bib10","doi-asserted-by":"crossref","first-page":"5968","DOI":"10.3390\/ijms23115968","article-title":"Advantages and limitations of animal schizophrenia models","volume":"23","author":"Bia\u0142o\u0144","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.114079_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2021.689193","article-title":"Effect of neonatal treatment with the NMDA receptor antagonist, MK-801, during different temporal windows of postnatal period in adult prefrontal cortical and hippocampal function","volume":"15","author":"Plataki","year":"2021","journal-title":"Front Behav. Neurosci."},{"key":"10.1016\/j.biopha.2022.114079_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.bbr.2015.01.010","article-title":"Ketamine administration during the second postnatal week induces enduring schizophrenia-like behavioral symptoms and reduces parvalbumin expression in the medial prefrontal cortex of adult mice","volume":"282","author":"Jeevakumar","year":"2015","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.biopha.2022.114079_bib13","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.neuropharm.2011.01.049","article-title":"Behavioral and neurochemical consequences of cortical oxidative stress on parvalbumin-interneuron maturation in rodent models of schizophrenia","volume":"62","author":"Powell","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2022.114079_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpsychires.2020.04.005","article-title":"The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model","volume":"126","author":"Mart\u00ednez-Pinte\u00f1o","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.biopha.2022.114079_bib15","doi-asserted-by":"crossref","first-page":"8495","DOI":"10.1021\/acs.jmedchem.6b00913","article-title":"Discovery of 8-trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine (JNJ-46356479), a selective and orally bioavailable mGlu2 receptor positive allosteric modulator (PAM","volume":"59","author":"Cid","year":"2016","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2022.114079_bib16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pnpbp.2015.02.012","article-title":"Perspectives on the mGluR2\/3 agonists as a therapeutic target for schizophrenia: still promising or a dead end","volume":"60","author":"Li","year":"2015","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2022.114079_bib17","doi-asserted-by":"crossref","unstructured":"Gass\u00f3 P., Mart\u00ednez-Pinte\u00f1o A., Rodr\u00edguez N., Madero S., G\u00f3mez M., Segura A.G., Garc\u00eda-Rizo C., Mor\u00e9n C., Mas S., Parellada E. Neuroprotective effect of the positive allosteric modulator of the mGluR2 JNJ-46356479 in human neuroblastoma cell cultures. Int J Mol Sci 2022 (under review).","DOI":"10.1016\/j.nsa.2022.100965"},{"key":"10.1016\/j.biopha.2022.114079_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fpsyt.2014.00032","article-title":"Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system","volume":"5","author":"Gruber","year":"2014","journal-title":"Front Psychiatr."},{"key":"10.1016\/j.biopha.2022.114079_bib19","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1021\/jm500496m","article-title":"Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor","volume":"57","author":"Cid","year":"2014","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2022.114079_bib20","article-title":"Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor","volume":"3","author":"Lavreysen","year":"2015","journal-title":"Pharm. Res. Perspect."},{"key":"10.1016\/j.biopha.2022.114079_bib21","article-title":"Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813","volume":"3","author":"Lavreysen","year":"2015","journal-title":"Pharm. Res. Perspect."},{"key":"10.1016\/j.biopha.2022.114079_bib22","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrd.2016.28","article-title":"Altering the course of schizophrenia: progress and perspectives","volume":"15","author":"Millan","year":"2016","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.biopha.2022.114079_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuron.2013.02.011","article-title":"Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver","volume":"78","author":"Schobel","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2022.114079_bib24","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/nm.4225","article-title":"Developmental timing and critical windows for the treatment of psychiatric disorders","volume":"22","author":"Mar\u00edn","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.114079_bib25","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-010-2052-z","article-title":"Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2\/3 receptor agonist","volume":"214","author":"Dedeurwaerdere","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopha.2022.114079_bib26","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/epi.14005","article-title":"Potent and selective pharmacodynamic synergy between the metabotropic glutamate receptor subtype 2-positive allosteric modulator JNJ-46356479 and levetiracetam in the mouse 6-Hz (44-mA) model","volume":"59","author":"Metcalf","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.biopha.2022.114079_bib27","first-page":"557","article-title":"NMDA receptor ablation on parvalbumin-positive inter","volume":"68","author":"Korotkova","year":"2010","journal-title":"Neurons Impairs Hippocampal Synchrony Spat. Represent. Work. Mem. Neuron"},{"key":"10.1016\/j.biopha.2022.114079_bib28","unstructured":"Franklin K.B., Paxinos G. Paxinos and Franklin\u2019s the mouse brain in stereotaxic coordinates. Academic Press 2013, fourth ed. An imprint of Elsevier, Amsterdam."},{"key":"10.1016\/j.biopha.2022.114079_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuropharm.2017.11.045","article-title":"NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update","volume":"142","author":"Cadinu","year":"2018","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.biopha.2022.114079_bib30","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s11064-018-2590-z","article-title":"Morin attenuates neurochemical changes and increased oxidative\/nitrergic stress in brains of mice exposed to ketamine: prevention and reversal of schizophrenia-like symptoms","volume":"43","author":"Ben-Azu","year":"2018","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.biopha.2022.114079_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.pnpbp.2013.04.006","article-title":"Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice","volume":"45","author":"Hou","year":"2013","journal-title":"Progr. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"21\u201322","key":"10.1016\/j.biopha.2022.114079_bib32","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1007\/s00213-015-3946-6","article-title":"PCP-based mice models of schizophrenia: differential behavioral, neurochemical and cellular effects of acute and subchronic treatments","volume":"232","author":"Casta\u00f1\u00e9","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopha.2022.114079_bib33","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuroscience.2016.07.028","article-title":"Acute phencyclidine administration induces c-Fos-immunoreactivity in interneurons in cortical and subcortical regions","volume":"334","author":"Hervig","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2022.114079_bib34","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.bbr.2017.06.013","article-title":"Disturbances of novel object exploration and recognition in a chronic ketamine mouse model of schizophrenia","volume":"332","author":"Hauser","year":"2017","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2022.114079_bib35","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fnbeh.2018.00079","article-title":"Immediate early genes, memory and psychiatric disorders: focus on c-Fos, Egr1 and Arc","volume":"12","author":"Gallo","year":"2018","journal-title":"Front Behav. Neurosci."},{"key":"10.1016\/j.biopha.2022.114079_bib36","first-page":"78","article-title":"Role of immediate-early genes in synaptic plasticity and neuronal ensembles underlying the memory trace","volume":"8","author":"Minatohara","year":"2015","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2022.114079_bib37","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1523\/JNEUROSCI.23-27-09116.2003","article-title":"Impaired long-term memory and NR2A-type NMDA receptor-dependent synaptic plasticity in mice lacking c-Fos in the CNS","volume":"23","author":"Fleischmann","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.114079_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13041-017-0293-z","article-title":"Targeting metabotropic glutamate receptors for novel treatments of schizophrenia","volume":"10","author":"Maksymetz","year":"2017","journal-title":"Mol. Brain"},{"key":"10.1016\/j.biopha.2022.114079_bib39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/13543776.2019.1637421","article-title":"mGluR2 positive allosteric modulators: an updated patent review (2013-2018)","volume":"29","author":"Trabanco","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.biopha.2022.114079_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.122","article-title":"Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls","volume":"5","author":"Batalla","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.biopha.2022.114079_bib41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpsychires.2013.09.017","article-title":"Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-na\u00efve first-episode schizophrenia patients","volume":"48","author":"Gass\u00f3","year":"2014","journal-title":"J. Psychiatr. Res"},{"key":"10.1016\/j.biopha.2022.114079_bib42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jpsychires.2017.08.003","article-title":"Microarray gene-expression study in fibroblast and lymphoblastoid cell lines from antipsychotic-na\u00efve first-episode schizophrenia patients","volume":"95","author":"Gass\u00f3","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.biopha.2022.114079_bib43","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.neuropharm.2018.05.019","article-title":"Juvenile treatment with mGluR2\/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3\u03b2","volume":"137","author":"Xing","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2022.114079_bib44","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-012-2845-3","article-title":"Enhancement of social novelty discrimination by positive allosteric modulators at metabotropic glutamate 5 receptors: adolescent administration prevents adult-onset deficits induced by neonatal treatment with phencyclidine","volume":"225","author":"Clifton","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopha.2022.114079_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ntt.2021.107053","article-title":"Sex-specific behavioral impairments produced by neonatal exposure to MK-801 are partially reversed by adolescent CDPPB treatment","volume":"89","author":"Miller-Rhodes","year":"2022","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.biopha.2022.114079_bib46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature09552","article-title":"Rethinking schizophrenia","volume":"468","author":"Insel","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.114079_bib47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tins.2011.10.004","article-title":"Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia","volume":"35","author":"Lewis","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.biopha.2022.114079_bib48","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00213-020-05700-y","article-title":"Neonatal phencyclidine and social isolation in the rat: effects of clozapine on locomotor activity, social recognition, prepulse inhibition, and executive functions deficits","volume":"238","author":"Hamieh","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopha.2022.114079_bib49","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.euroneuro.2019.03.007","article-title":"Atypical but not typical antipsychotic drugs ameliorate phencyclidine-induced emotional memory impairments in mice","volume":"29","author":"Adem","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2022.114079_bib50","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12888-020-02509-z","article-title":"Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action","volume":"20","author":"Zhou","year":"2020","journal-title":"BMC Psychiatry"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222014688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:19:58Z","timestamp":1779794398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222014688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":50,"alternative-id":["S0753332222014688"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114079","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early treatment with JNJ-46356479, a mGluR2 modulator, improves behavioral and neuropathological deficits in a postnatal ketamine mouse model of schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.114079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114079"}}